ATTY Aaron Siri - A Call for Transparent Vaccine Data Analysis to Protect Our Children

Del Bigtree recently engaged in a discussion with Aaron Siri about the critical issue of vaccine safety, particularly regarding the childhood vaccine schedule. Bigtree raised concerns about the lack of placebo-controlled trials for vaccines already on the market, noting that ethical constraints prevent such studies now, as withholding a vaccine deemed standard care is considered unethical.

He asked what can be done to address the safety of the 16-17 vaccines administered in numerous doses, which, according to Bigtree, were often licensed without rigorous safety testing.Siri emphasized the need for transparency as a starting point. He urged public health authorities and media outlets to openly acknowledge the limitations of the clinical trials used to license childhood vaccines.

For instance, he highlighted that the first hepatitis B vaccine was approved based on a trial involving only 147 children, with just five days of safety monitoring and no control group. Siri argued that admitting these shortcomings is essential to having an honest conversation about vaccine safety.

Rather than immediately conducting new placebo-controlled trials, Siri proposed a practical alternative: leveraging existing healthcare datasets from large HMOs like Kaiser Permanente, Harvard Pilgrim, or Henry Ford. These organizations maintain comprehensive records of medical and insurance data, tracking patient health outcomes over time.

Siri suggested analyzing these datasets by comparing two groups: children who received no vaccines and those who received one or more. By focusing on individuals with complete medical records from birth, researchers could assess health outcomes, such as rates of chronic diseases, asthma, autoimmune disorders, or neurological conditions, between the two groups.

Siri stressed that this approach would not require leaving any child unvaccinated, as it relies on historical data. If the analysis shows that unvaccinated children are as healthy or less healthy than their vaccinated peers, the results could reassure parents and affirm the safety of the vaccine schedule.

However, if the data reveal higher rates of chronic conditions among vaccinated children, as some smaller studies have suggested, Siri argued that this would not necessitate eliminating vaccines. Instead, it would prompt further investigation into specific vaccines and their effects, similar to how other medications, like statins, are studied and managed despite known risks.

Siri’s proposal offers a feasible path forward: use real-world data to evaluate vaccine safety transparently. He called for an end to dismissing concerns about vaccine injuries and urged the scientific community to conduct these comparative studies. If disparities in health outcomes emerge, more granular research could follow to refine the vaccine schedule and protect public health.

This approach, Siri concluded, respects both the need for evidence-based policy and the concerns of parents seeking clarity on the safety of childhood vaccines.